OERIS offers extended antiemetic coverage through a single injection that effectively prevents both acute and delayed CINV for up to five days
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Kulzer has consolidated the production of its core product, artificial teeth, at its facility in Germany
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
AI-powered cardiometabolic wellness platform for India’s workforce
Subscribe To Our Newsletter & Stay Updated
